CN119506229A - A kind of attenuated bovine lumpy skin disease virus LSDV-DQ and its application - Google Patents
A kind of attenuated bovine lumpy skin disease virus LSDV-DQ and its application Download PDFInfo
- Publication number
- CN119506229A CN119506229A CN202510065200.3A CN202510065200A CN119506229A CN 119506229 A CN119506229 A CN 119506229A CN 202510065200 A CN202510065200 A CN 202510065200A CN 119506229 A CN119506229 A CN 119506229A
- Authority
- CN
- China
- Prior art keywords
- skin disease
- disease virus
- lsdv
- bovine
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 72
- 241000609846 Lumpy skin disease virus Species 0.000 title claims abstract description 14
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 55
- 229960005486 vaccine Drugs 0.000 claims abstract description 20
- 238000004321 preservation Methods 0.000 claims abstract description 10
- 230000001018 virulence Effects 0.000 claims abstract description 6
- 241000700665 Sheeppox virus Species 0.000 claims description 3
- 229940031567 attenuated vaccine Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 abstract description 52
- 241000700664 Capripoxvirus Species 0.000 abstract description 6
- 230000001900 immune effect Effects 0.000 abstract description 4
- 229940125575 vaccine candidate Drugs 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 241000700625 Poxviridae Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 208000003930 Lumpy Skin Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a bovine nodular skin disease virus LSDV DQ with weak virulence and application thereof, belonging to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is fully attenuated and has good immune effect. The invention provides a bovine nodular skin disease virus strain with weak virulence, which is named as capripoxvirus LSDV-DQ, has a preservation number of CCTCC NO: V2024113, and is preserved in China center for type culture Collection with a preservation date of 2024 and 12 months and 2 days. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular skin diseases.
Description
Technical Field
The invention belongs to the technical field of attenuated strains, and particularly relates to bovine nodular skin disease virus LSDV-DQ with weak virulence and application thereof.
Background
Niu Jiejie dermatological disorders (Lumpy SKIN DISEASE, LSD) an important infectious disease of cattle. The disease is caused by bovine nodular skin disease virus (Lumpy SKIN DISEASE virus, LSDV), which belongs to the family poxviridae (Poxviridae), and forms the genus capripoxvirus (Capripox 5 virus) with capripoxvirus (Sheeppox virus, SPPV) and capripoxvirus (Goatpox virus, GTPV). At present, no commercial product exists for the vaccine against the disease, most of researches are remained in the inactivated vaccine, but the inactivated vaccine has the problems of high cost and poor immune effect, and human intervention is needed for inactivation, so that an attenuated vaccine strain with good immune effect needs to be provided.
Disclosure of Invention
The invention aims to provide a bovine nodular skin disease virus vaccine strain which is fully attenuated and has good immune effect.
The invention provides a bovine nodular skin disease virus strain (Lumpy SKIN DISEASE virus) LSDV-DQ with weak virulence, which is named as capripoxvirus LSDV-DQ, and has a preservation number of CCTCC NO: V2024113, and is preserved in China center for type culture Collection with a preservation date of 2024, 12 months and 2 days.
The invention provides an attenuated vaccine of bovine nodular skin disease virus, which comprises the bovine nodular skin disease virus strain.
Further defined, the vaccine is a monovalent or multivalent vaccine.
Further defined, the vaccine further comprises a pharmaceutically acceptable adjuvant.
Further defined, the vaccine is in the form of an injection.
Further defined, the bovine nodular skin disease virus content is 10 3TCID50-106TCID50.
The invention provides an application of the bovine nodular skin disease virus strain in preparing a vaccine for preventing or treating bovine nodular skin disease.
Further defined, the bovine nodular skin disease virus is present in an amount of 10 3TCID50-106TCID50.
The method has the beneficial effects that a attenuated bovine nodular skin disease virus strain LSDV-DQ with good safety is obtained, the immunized bovine nodular skin disease virus LSDV-DQ (10 5TCID50 is injected into each cow subcutaneously) is not ill, the nucleic acid and antibody of the same cattle are negative, no horizontal transmission phenomenon is shown, the vaccine strain with sufficient attenuation is obtained, and an attenuation experiment shows that the Niu Jiejie type skin disease virus LSDV-DQ can provide 100% immune protection for the 10 6TCID50 virulent strain attenuation and can be used as a safe and effective vaccine for preventing and controlling bovine nodular skin disease.
[ Biological preservation information ] A virulent bovine nodular skin disease virus strain (Lumpy SKIN DISEASE virus), named capripoxvirus LSDV-DQ, has a preservation number of CCTCC NO: V2024113, is preserved in China center for type culture Collection, has a preservation date of 2024, 12 months and 2 days, and has a preservation address of university of Wuhan, china.
Drawings
FIG. 1 is a graph showing the results of inoculation of bovine nodular skin disease virus with different cells, wherein FIG. A shows the results of inoculation of bovine nodular skin disease virus with BT bovine testis cells for 96 hours, FIG. B shows the results of inoculation of bovine nodular skin disease virus with LT sheep testis cells for 48 hours, and FIG. C shows the results of inoculation of bovine nodular skin disease virus with Vero-E6 cells for 96 hours;
FIG. 2 is a graph showing the results of PCR identification of bovine nodular skin disease virus inoculated cells;
FIG. 3 is a graph showing the results of a bovine nodular skin disease virus growth curve, wherein XJ is bovine nodular skin disease virus strain LSDV-XJ, and DQ is bovine nodular skin disease virus strain LSDV-DQ;
FIG. 4 is a graph showing the results of comparing plaque formation between a novel isolate DQ and a virulent strain XJ, wherein XJ is bovine nodular skin disease virus strain LSDV-XJ, and DQ is bovine nodular skin disease virus strain LSDV-DQ;
FIG. 5 is a graph showing the results of changes in body temperature of a vaccinated bovine nodular skin disease virus, XJ is bovine nodular skin disease virus strain LSDV-XJ, DQ is bovine nodular skin disease virus strain LSDV-DQ;
FIG. 6 is a graph showing the results of detection and detoxification in blood, wherein XJ is bovine nodular skin disease virus strain LSDV-XJ, and DQ is bovine nodular skin disease virus strain LSDV-DQ;
FIG. 7 is a graph showing the results of detection and detoxification in eyes, XJ is bovine nodular skin disease virus strain LSDV-XJ, DQ is bovine nodular skin disease virus strain LSDV-DQ;
FIG. 8 is a graph showing the results of detection and detoxification in the nose, XJ is bovine nodular skin disease virus strain LSDV-XJ, DQ is bovine nodular skin disease virus strain LSDV-DQ;
FIG. 9 is a graph showing the results of intraoral test for the bovine nodular skin disease virus strain LSDV-XJ, and DQ is the bovine nodular skin disease virus strain LSDV-DQ;
FIG. 10 is a graph showing the results of neutralizing antibody production after immunization;
FIG. 11 is a graph showing the results of clinical detoxification cases after detoxification.
Detailed Description
LSDV-XJ describes the isolation and identification of bovine nodular skin disease virus for the first time in China, zhang Minmin, 2020, which is LSDV/China/Xinjiang/2019 strain (Xinjiang/2019).
LSDV-DQ is also referred to herein as DQ, LSDV-XJ is also referred to herein as XJ.
EXAMPLE 1 isolation of Niu Jiejie dermatological strains LSDV-DQ
1. Virus isolation in the scab of the nodular cast of the sick cow, fully grinding the scab by a tissue grinder, inoculating susceptible cells (sheep testis cells) into the grinding supernatant, and separating to obtain the suspected bovine nodular skin disease virus.
2. Identification of suspected bovine nodular skin disease virus obtained in step 1 was inoculated with sheep testis cells (LT), vero-E6, BT bovine testis cells (BT) for 48 and 96 hours, respectively, and the cells were subjected to obvious cytopathy (FIG. 1), and then the infected cells were subjected to PCR monitoring, with primers of 5 'atgagccatccattttcaactc 3' (SEQ ID NO. 1), 5'tcagtttatcatataagttcc 3' (SEQ ID NO. 2), and as a result, it was demonstrated that all cells showing cytopathy after inoculation were amplified to give the expected fragments (FIG. 2). These results all demonstrate that the isolated virus is LSDV, designated bovine nodular skin disease strain LSDV-DQ.
Isolation of strain biological characterization Studies bovine nodular skin disease Virus strain LSDV-DQ was compared with LSDV-XJ isolate isolated in the laboratory (disclosed in our country for the first isolation and identification of bovine nodular skin disease Virus, zhang Minmin, 2020). The two strains were infected at 0.5MOI, sampled and assayed at different time points, and finally, bovine nodular skin disease strains LSDV-DQ and LSDV-XJ were found to have the same trend in growth curves, with the highest titers also approaching, respectively 10 5.83TCID50/0.1 ml and 10 5.75TCID50/0.1 ml, and Niu Jiejie dermatological disease strains LSDV-DQ and LSDV-XJ having similar trend in growth, if shown in FIG. 3. In addition, plaque forming capacity of both strains was also compared. The results indicated that Niu Jiejie dermatological strains LSDV-DQ form smaller plaques of 280 and 440 microns, respectively (fig. 4).
EXAMPLE 2 use of bovine nodular skin disease Virus strain LSDV-DQ
1. Detoxification experiments bovine sarcoidosis strain LSDV-DQ (LSDV-DQ group) of example 1 was inoculated at a high dose of 10 5TCID50 (n=4), compared to virulent strain LSDV-XJ (LSDV-XJ group) (n=5), and the state (spirit and diet) and body temperature of the experimental cattle were observed daily.
The results showed that after inoculation with bovine nodular skin disease virus strain LSDV-DQ, there was a fever at both ends and the fever was only at a critical value of 39.5C, whereas all cattle in LSDV-XJ group had a fever and some were above 40C, as shown in FIG. 5. The detoxification cases are shown in FIGS. 6-9, and the viral load in each sample type of LSDV-DQ group is lower than LSDV-XJ group.
2. Immunization experiments bovine 10 heads were divided into two groups, one group being PBS control group and one group being LSDV-DQ group, and 10 3TCID50 were inoculated subcutaneously per head.
One immunization with Niu Jiejie strain LSDV-DQ resulted in ideal neutralizing antibody levels, with all experimental cattle having neutralizing antibodies at week 2 post immunization, and the highest antibody titers reached 1:28 by week 4 post immunization (fig. 10).
3. Toxin expelling experiments, namely, toxin expelling is carried out subcutaneously at the 4 th week after immunization, and the toxin expelling dosage is 10 6TCID50 per head. After toxicity attack, the clinical state of the experimental cattle is observed, and anticoagulation is collected for quantitative PCR detection. The results show that after the immune group attacks the toxin, the cattle feed normally, and the symptoms of mental depression and nodules are not generated, while the PBS group has typical LSD symptoms. For the anticoagulation assay, the results are shown in FIG. 11, where the viral load of LSDV-DQ groups is only 56 copies at maximum, significantly lower than 15511 copies of PBS-naive groups.
EXAMPLE 3 preparation of live vaccine
The live vaccine is prepared by using bovine nodular skin disease virus strain LSDV-DQ as live vaccine and infecting LT cells with 0.5MOI to propagate virus to obtain great amount of propagated vaccine strains, which are bovine nodular skin disease virus strains.
EXAMPLE 4 preparation of lyophilized viral vaccine strains
Niu Jiejie-dermatological virus strain LSDV-DQ is infected with LT cells at a MOI of 0.5 to reproduce virus, virus is collected in 5-7 days, repeated freeze thawing is carried out three times at-70 ℃, then centrifugation is carried out with 5000rmp to remove cell debris, the remaining supernatant is mixed with a freeze-drying protective agent 1:1, and split charging is carried out in penicillin bottles, firstly, the freeze-drying virus strain is obtained after 6h at-20 ℃ and 4h at-80 ℃ and then 24h in a freeze dryer (-40 ℃).
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510065200.3A CN119506229A (en) | 2025-01-16 | 2025-01-16 | A kind of attenuated bovine lumpy skin disease virus LSDV-DQ and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510065200.3A CN119506229A (en) | 2025-01-16 | 2025-01-16 | A kind of attenuated bovine lumpy skin disease virus LSDV-DQ and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119506229A true CN119506229A (en) | 2025-02-25 |
Family
ID=94662340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510065200.3A Pending CN119506229A (en) | 2025-01-16 | 2025-01-16 | A kind of attenuated bovine lumpy skin disease virus LSDV-DQ and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119506229A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114836356A (en) * | 2022-06-06 | 2022-08-02 | 南京农业大学 | Lawsonia intracellularis attenuated vaccine strain, vaccine and application thereof |
| CN117025551A (en) * | 2022-08-12 | 2023-11-10 | 金宇保灵生物药品有限公司 | Bovine nodular skin disease virus strain, inactivated vaccine prepared from bovine nodular skin disease virus strain and preparation method of inactivated vaccine |
| CN117384965A (en) * | 2023-09-07 | 2024-01-12 | 中国农业科学院兰州兽医研究所 | Method for constructing bovine nodular skin disease virus TK gene deletion strain LSDV-△TK |
-
2025
- 2025-01-16 CN CN202510065200.3A patent/CN119506229A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114836356A (en) * | 2022-06-06 | 2022-08-02 | 南京农业大学 | Lawsonia intracellularis attenuated vaccine strain, vaccine and application thereof |
| CN117025551A (en) * | 2022-08-12 | 2023-11-10 | 金宇保灵生物药品有限公司 | Bovine nodular skin disease virus strain, inactivated vaccine prepared from bovine nodular skin disease virus strain and preparation method of inactivated vaccine |
| CN117384965A (en) * | 2023-09-07 | 2024-01-12 | 中国农业科学院兰州兽医研究所 | Method for constructing bovine nodular skin disease virus TK gene deletion strain LSDV-△TK |
Non-Patent Citations (4)
| Title |
|---|
| ANDY HAEGEMAN ET AL.: "Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines", 《VACCINES》, vol. 9, 8 May 2021 (2021-05-08), pages 2 - 3 * |
| ZAHRA BAMOUH ET AL.: "Investigation of Post Vaccination Reactions of Two Live Attenuated Vaccines against Lumpy Skin Disease of Cattle", 《VACCINES》, vol. 9, no. 621, 8 June 2021 (2021-06-08), pages 1 - 15 * |
| 何菊 等: "牛结节性皮肤病疫苗研究进展", 《中国奶牛》, vol. 6, 31 December 2024 (2024-12-31), pages 27 - 31 * |
| 王宇 等: "山羊痘弱毒疫苗（AV41 株）接种途径 和剂量对牛抗体反应的影响", 《华中农业大学学报》, vol. 42, no. 2, 31 March 2023 (2023-03-31), pages 24 - 31 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2957472C (en) | Attenuated bovine coronavirus and related vaccines | |
| CN109576185B (en) | Probiotic mixed preparation with anti-influenza capacity and application thereof | |
| JP2004536106A (en) | Mycoplasma bovis vaccine and method for reducing pneumonia in animals | |
| US11660337B2 (en) | Triple live vaccine of canine distemper virus, canine parvovirus and canine infectious hepatitis virus | |
| WO2015109578A1 (en) | Swine mycoplasmal pneumonia attenuated live vaccine and use thereof | |
| CN1062770C (en) | Vaccine both for hepatitis A and measles and production method therefor | |
| CN103773739B (en) | A kind of feline panleukopenia virus attenuated vaccine strain and application thereof | |
| CN113073083B (en) | Canine parvovirus low virulent strain, vaccine composition prepared from same and application of vaccine composition | |
| CN119506229A (en) | A kind of attenuated bovine lumpy skin disease virus LSDV-DQ and its application | |
| CN104800842B (en) | A kind of goatpox, sheep pox divalence cell weak-toxic vaccine and its preparation method and application | |
| KR102615970B1 (en) | Hyperimmune Serum Against Diarrhea Causing Viruses in Bovine, Composition Containing Thereof, Method of Producing Thereof, and Method of Preventing and Treating Bovine Viral Diarrhea Using Thereof | |
| CN109432413B (en) | A kind of forest encephalitis virus inactivated vaccine and preparation method thereof | |
| RU2325437C1 (en) | Attenuated strain of goatpox virus | |
| CN119464232A (en) | A kind of attenuated bovine lumpy skin disease virus LSDV-75 and its application | |
| JP2021506777A (en) | Vaccine to protect against streptococcal infection | |
| CN115554396A (en) | Feline calicivirus and feline herpesvirus bivalent vaccine and preparation method and application thereof | |
| CN104388394B (en) | Mink Parvovirus attenuated vaccine strain and its purposes in Mink Parvovirus attenuated vaccine is prepared | |
| CN106520623A (en) | Serum 7 type haemophilus parasuis low virulent strain and application thereof | |
| CN108703952B (en) | Freeze-drying protective agent for swine fever oral attenuated freeze-dried vaccine and application | |
| CN117887648B (en) | Recombinant lactic acid bacteria composition expressing H9N2 subtype avian influenza virus antigen protein and application thereof | |
| CN113827716B (en) | Canine distemper virus attenuated strain, vaccine composition prepared from same and application thereof | |
| RU2147609C1 (en) | Strain of virus canine parvovirus "riel" for preparing vaccine against parvoviral infection in carnivores and vaccine "vladivak" against viral diseases in carnivores based on said | |
| CN104306994A (en) | Japanese schistosomiasis vaccine combined immunizing method and application of Japanese schistosomiasis vaccine | |
| CN113583970B (en) | A medicine for preventing or resisting coronavirus transmission and pathopoiesia, and its preparation method | |
| CN103861095B (en) | Containing the vaccine combination and its preparation method and application of mycoplasmal pneumonia of swine antigen and pig streptococcicosis antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |